Literature DB >> 10912779

Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.

A Zhou1, L Yu, J Li, J Zhang, H Wang.   

Abstract

The present study compared renoprotective effects of angiotensin II type I receptor antagonist (AT1RA) with angiotensin converting enzyme inhibitor (ACEI), and their influence on the renin-angiotensin-system (RAS). Experimental nephrotic syndrome was induced in SD rats by repeated peritoneal injections of puromycin. Twenty-eight rats were randomly divided into four groups: normal control, nephrotic control, ACEI-treated, and AT1RA-treated groups. Serum, urine, and renal tissue were collected for study at the end of 12 weeks. Compared with those of the nephrotic control group, urinary protein was less and renal function was better in both treated groups. The glomerular and interstitial damage indexes of both ACEI- and AT1RA-treated rats were lower than those of nephrotic control rats, with no significant difference observed between the two treated groups. Local renal ACE activity and angiotensin II concentration were elevated in nephrotic rats (p< 0.01). However, there is no significant difference in circulating RAS, renal tissue renin, and aldosterone between the normal control and nephrotic control rats. As expected, enalapril inhibited the local renal ACE activity and significantly decreased angiotensin II (p< 0.01). Intrarenal ACE activity and angiotensin concentration returned to normal levels after treatment with irbesartan (p< 0.01). In conclusion, AT1RA and ACEI have comparable renal protective effects, and these protective effects were associated with the inhibition of intrarenal ANG II.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912779     DOI: 10.1291/hypres.23.391

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  5 in total

1.  Association of fibronectin Msp iv polymorphism and diabetic nephropathy susceptibility in Chinese Han population.

Authors:  Jinxiang Gao; Xuezhong Zhang; Huiling Diao; Yunqi Liu; Min Lv; Hua Dong; Xiaomin Zhang; Yaning Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.

Authors:  Gang Zhao; Hong Zhao; Ling Tu; Xizhen Xu; Changlong Zheng; Meihua Jiang; Peihua Wang; Daowen Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-02-14

Review 3.  Angiotensin receptor blockers in diabetic nephropathy.

Authors:  D A Price; N K Hollenberg
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

4.  Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats.

Authors:  Xiaofei Si; Peng Li; Yan Zhang; Yan Zhang; Wei Lv; Dong Qi
Journal:  Biomed Rep       Date:  2013-10-09

5.  Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.

Authors:  Ye Zhu; Ze-Liang Li; Ao Ding; Hui Yang; Wei-Ping Zhu; Tong-Xia Cui; Hui-Tao Zhang; Hua Zhang
Journal:  Drug Des Devel Ther       Date:  2019-10-22       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.